EHA 2021 | Current CAR-T treatments for T-ALL and next steps
Jing Pan
• 15 Jun 2021
Jing Pan, MD, Beijing Boren Hospital, Beijing, China, talks on chimeric antigen receptor T-cell (CAR-T) therapies for T-cell acute lymphoblastic leukemia (T-ALL). Dr Pan highlights the findings of a preclinical study from 2016 and more recent advances in CAR-T therapy for T-ALL, including autologous CD7 CAR-T therapy and universal CD7 CAR-T therapy. Dr Pan also discusses the next steps for CAR-T therapy for T-ALL, in particular commenting on challenges around persistence for universal CAR-T cells. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
